U.S. health officials are telling travelers aged 60 and older to avoid a chikungunya vaccine while they investigate possible ...

Adults over the age of 60 are recommended not to get the chikungunya vaccine to prevent the mosquito-borne illness due to two ...

The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 ...

Chikungunya is a mosquito-borne tropical disease that causes intense joint pain and fever. Although it is rare in the U.S., about 100 to 200 cases are reported annually, mostly among Americans ...

The U.S. government is advising that international travelers age 60 and older not get a chikungunya vaccine as it ...

The FDA and CDC have also recommended pausing the use of Ixchiq in seniors 60 years and older while safety investigations are ...

Both the FDA and EMA have suspended Ixchiq’s use in older adults after post-marketing serious adverse events that include two ...

Valneva (VALN) stock is in focus as the U.S. recommends a pause in the company's chikungunya vaccine Ixchiq in adults 60+ ...

Short interest in Valneva SE (NASDAQ:VALN) decreased during the last reporting period, falling from 19.50K to 9.94K. This put 0.01% of the company's publicly available shares short. Short interest ...

Valneva SE offers exposure to a robust travel vaccine portfolio that includes Ixiaro, Dukoral, and Ixchiq. Read what ...

The European Union's health regulator said on Wednesday it was reviewing French drugmaker Valneva's chikungunya vaccine after ...